Literature DB >> 19594505

The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment.

Philip D Harvey1, Jean M Endicott, Antony D Loebel.   

Abstract

BACKGROUND: While the factor structure of clinical symptoms in schizophrenia has been examined and provided crucial information about the illness, there is much less information available in bipolar disorder. This study examined the structure of symptoms of bipolar disorder at an unmedicated baseline assessment and after double-blind treatment with ziprasidone, haloperidol, or placebo. We hypothesized, consistent with recent studies of schizophrenia, that the factor structure after treatment would be similar to the structure of untreated symptoms at study baseline.
METHODS: Hospitalized patients with manic (n = 363) or mixed (n = 71) bipolar episodes were rated with the Hamilton Depression Rating Scale (HAM-D) and the Mania Rating Scale [(MRS); derived from the Schedule for Affective Disorders and Schizophrenia - Change Bipolar Scale]. After 21 days of double-blind treatment, all patients were again rated with the MRS and HAM-D.
RESULTS: Exploratory orthogonal factor analysis (varimax rotation) including both HAM-D total scores and the MRS items found different five-factor solutions for mixed and manic patients at the unmedicated baseline assessment. Confirmatory modeling indicated that these models, with some modifications, fit the data well. At the endpoint, however, a single-factor solution was found for mixed and manic groups. IMPLICATIONS: Symptomatology in bipolar disorder is multifactorial in an acute and unmedicated state, with slightly different factor structures for mixed and manic episodes. Following treatment, a single severity dimension is detected. These results suggest that symptom dimensions in mania may be different from those seen in schizophrenia, where different elements of symptoms have been proven to have different functional correlates and treatment response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19594505     DOI: 10.1111/j.1399-5618.2008.00634.x

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  7 in total

1.  Affective symptom dimensions in early-onset psychosis over time: a principal component factor analysis of the Young Mania Rating Scale and the Hamilton Depression Rating Scale.

Authors:  Marta Rapado-Castro; Carmen Moreno; Gonzalo Salazar de Pablo; Dolores Moreno; Ana Gonzalez-Pinto; Beatriz Paya; Josefina Castro-Fonieles; Inmaculada Baeza; Montserrat Graell; Celso Arango
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-05-30       Impact factor: 4.785

2.  An item response theory evaluation of the young mania rating scale and the montgomery-asberg depression rating scale in the systematic treatment enhancement program for bipolar disorder (STEP-BD).

Authors:  James J Prisciandaro; Bryan K Tolliver
Journal:  J Affect Disord       Date:  2016-07-13       Impact factor: 4.839

3.  The structure of the Montgomery-Åsberg depression rating scale over the course of treatment for depression.

Authors:  Lena C Quilty; Jennifer J Robinson; Jean-Pierre Rolland; Filip De Fruyt; Frédéric Rouillon; R Michael Bagby
Journal:  Int J Methods Psychiatr Res       Date:  2013-08-19       Impact factor: 4.035

4.  Signs and symptoms of acute mania: a factor analysis.

Authors:  Raveen Hanwella; Varuni A de Silva
Journal:  BMC Psychiatry       Date:  2011-08-19       Impact factor: 3.630

5.  Patterns of response to aripiprazole, lithium, haloperidol, and placebo across factor scores of mania.

Authors:  Michael J Ostacher; Trisha Suppes; Alan C Swann; James M Eudicone; Wally Landsberg; Ross A Baker; Berit X Carlson
Journal:  Int J Bipolar Disord       Date:  2015-05-05

Review 6.  The structure of mania: An overview of factorial analysis studies.

Authors:  Diego J Martino; Marina P Valerio; Gordon Parker
Journal:  Eur Psychiatry       Date:  2020-02-10       Impact factor: 5.361

7.  Anticipating the direction of symptom progression using critical slowing down: a proof-of-concept study.

Authors:  Marieke J Schreuder; Johanna T W Wigman; Robin N Groen; Els Weinans; Marieke Wichers; Catharina A Hartman
Journal:  BMC Psychiatry       Date:  2022-01-21       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.